Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

Fig. 1

Number of immune checkpoint inhibitor FDA approvals by tumor type: The colors in the key denote whether PD-L1 testing was approved (blue) or not approved (green) as a companion diagnostic. Abbreviations: GEJ = gastro-esophageal junction; HCC = hepatocellular carcinoma; HL = Hodgkin’s Lymphoma; NSCLC = non-small cell lung cancer; PMBCL = primary mediastinal B-cell lymphoma; RCC = renal cell carcinoma; SCC = squamous cell carcinoma; SCLC = small cell lung cancer

Back to article page